Aim:Neuroblastoma (NB), a pediatric tumor with high prevalence and mortality rates, was the focus of this investigation. This study aimed to assess the combined antitumor potential of theranekron (Trn) and cisplatin in this cell line. The interaction between theranekron (10-100 µM) and cisplatin (40 µM) was examined.Material and Methods:The cytotoxicity of theranekron was evaluated using MTT assays, cell volume analyses, apoptosis assessments, and measurements of mitochondrial membrane potential. These evaluations were conducted over a 24-hour incubation period.Results:The coadministration of 100 µM theranekron with cisplatin exhibited a cytotoxic effect of approximately 60%. Furthermore, it led to a reduction of up to 38% in cell volume. Notably, SH-SY5Y cells demonstrated an early apoptosis rate of 34.4%, accompanied by an eightfold decrease in mitochondrial membrane potential compared to the control group.Conclusion:Theranekron demonstrated synergism and significantly enhanced the efficacy of cisplatin (P<0.001). Nevertheless, further in-depth investigations are necessary to elucidate the intricacies of these synergistic effects.